These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

836 related articles for article (PubMed ID: 33758291)

  • 1. Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks.
    Kao YC; Chen TH; Liu CH; Hwang JS; Hsiao CC; Lin YS; Mao CT; Hung MJ; Li YR
    Sci Rep; 2021 Mar; 11(1):6697. PubMed ID: 33758291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients.
    Liu CH; Chen TH; Lin MS; Hung MJ; Chung CM; Cherng WJ; Lee TH; Lin YS
    J Clin Endocrinol Metab; 2016 Aug; 101(8):2994-3001. PubMed ID: 27270238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes.
    Park SY; Jun JE; Jeong IK; Ahn KJ; Chung HY; Hwang YC
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1883-1890. PubMed ID: 38175670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
    Giugliano RP; Cannon CP; Blazing MA; Nicolau JC; Corbalán R; Špinar J; Park JG; White JA; Bohula EA; Braunwald E;
    Circulation; 2018 Apr; 137(15):1571-1582. PubMed ID: 29263150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial.
    Oliver W; Giugliano RP
    Curr Atheroscler Rep; 2023 Mar; 25(3):85-93. PubMed ID: 36763180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.
    Rotella CM; Zaninelli A; Le Grazie C; Hanson ME; Gensini GF
    Lipids Health Dis; 2010 Jul; 9():80. PubMed ID: 20663203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
    Khunti K; Danese MD; Kutikova L; Catterick D; Sorio-Vilela F; Gleeson M; Kondapally Seshasai SR; Brownrigg J; Ray KK
    JAMA Netw Open; 2018 Dec; 1(8):e185554. PubMed ID: 30646277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study.
    Chang SH; Wu LS; Lee CH; Kuo CT; Liu JR; Wen MS; Chen WJ; See LC; Yeh YH
    Int J Cardiol; 2015; 190():20-5. PubMed ID: 25912112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
    Oyama K; Giugliano RP; Blazing MA; Park JG; Tershakovec AM; Sabatine MS; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2021 Oct; 78(15):1499-1507. PubMed ID: 34620406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
    Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
    Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
    Li L; Zhang M; Su F; Li Y; Shen Y; Shen J; Zhang D
    Lipids Health Dis; 2015 Feb; 14():10. PubMed ID: 25879728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
    Murphy SA; Cannon CP; Blazing MA; Giugliano RP; White JA; Lokhnygina Y; Reist C; Im K; Bohula EA; Isaza D; Lopez-Sendon J; Dellborg M; Kher U; Tershakovec AM; Braunwald E
    J Am Coll Cardiol; 2016 Feb; 67(4):353-361. PubMed ID: 26821621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
    Le NA; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
    J Am Heart Assoc; 2015 Oct; 4(10):e001675. PubMed ID: 26486166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
    Lancellotti P; Pierard LA; Scheen AJ
    Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study.
    Jun JE; Jeong IK; Ahn KJ; Chung HY; Hwang YC
    Eur J Prev Cardiol; 2024 Aug; 31(10):1205-1213. PubMed ID: 38408362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study).
    Bardini G; Giorda CB; Pontiroli AE; Le Grazie C; Rotella CM
    Cardiovasc Diabetol; 2010 May; 9():20. PubMed ID: 20492655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial.
    Eisen A; Cannon CP; Blazing MA; Bohula EA; Park JG; Murphy SA; White JA; Giugliano RP; Braunwald E;
    Eur Heart J; 2016 Dec; 37(48):3576-3584. PubMed ID: 27569841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.